title: Management of ventricular arrhythmias in structural heart disease.
abstract: Ventricular arrhythmias (VA) are a source of significant morbidity and mortality in patients with structural heart disease (SHD). The advent of the implantable cardiac defibrillator (ICD) has had a positive effect on mortality, but the associated morbidity remains a significant problem. Modern treatment of VA has advanced far beyond medical therapy and includes strategies as simple as intelligent ICD programming and as complex as catheter ablation (CA). In these pages, the spectrum of management strategies will be discussed; from anti-arrhythmic drugs and ICD implantation and programming to CA and autonomic modulation. The focus of this review will be on strategies for secondary prevention of VA in patients with SHD, supported by clinical evidence for their utilization.
authors.affiliation: Division of Cardiology, Department of Medicine, Westchester Medical Center, New York Medical College , Valhalla, New York , USA.
authors.forename: Jason T
authors.initials: JT
authors.lastname: Jacobson
authors.forename: Sei
authors.initials: S
authors.lastname: Iwai
authors.forename: Wilbert
authors.initials: W
authors.lastname: Aronow
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D058406:Cardiac Resynchronization Therapy; D009202:Cardiomyopathies / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D017115:Catheter Ablation; D017147:Defibrillators, Implantable; D006801:Humans; D014693:Ventricular Fibrillation / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D054141:Ventricular Flutter / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*
chemical_list: D000889:Anti-Arrhythmia Agents
keywords: Ventricular tachycardia; ablation; cardiomyopathy; implantable defibrillator; sympathetic denervation; ventricular fibrillation